Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luxeptinib - Aptose Biosciences/CrystalGenomics

Drug Profile

Luxeptinib - Aptose Biosciences/CrystalGenomics

Alternative Names: CG-026806; CG-806

Latest Information Update: 06 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CrystalGenomics
  • Developer Aptose Biosciences; CrystalGenomics
  • Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoindoles; Phenylurea compounds; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Aurora kinase inhibitors; Discoidin domain receptor 2 antagonists; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin 6 inhibitors; Lyn protein-tyrosine kinase inhibitors; NLRP3 protein inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-akt inhibitors; Proto-oncogene protein c-ret inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Preclinical Haematological malignancies; Mantle-cell lymphoma

Most Recent Events

  • 06 Jun 2024 Luxeptinib is still in phase-I development in Chronic-lymphocytic-leukaemia (Second-line therapy or greater), Acute myeloid leukaemia (Second-line therapy or greater), Myelodysplastic syndromes, Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (PO, Capsule)
  • 06 Jun 2024 Luxeptinib is still in preclinal development in Haematological malignancies in South Korea (PO, Capsule)
  • 06 Jun 2024 Luxeptinib is still in preclinical development in Mantle cell lymphoma in Canada (Unspecified)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top